Windtree Therapeutics’ (WINT) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Windtree Therapeutics (NASDAQ:WINT) in a research note released on Wednesday,Benzinga reports. The brokerage currently has a $7.00 target price on the stock. HC Wainwright also issued estimates for Windtree Therapeutics’ Q4 2024 earnings at ($0.92) EPS, FY2024 earnings at ($5.66) EPS and FY2025 earnings at ($2.86) EPS.

Windtree Therapeutics Trading Down 4.7 %

WINT stock opened at $0.37 on Wednesday. The company has a market capitalization of $3.33 million, a P/E ratio of -0.02 and a beta of 0.54. Windtree Therapeutics has a twelve month low of $0.35 and a twelve month high of $16.74. The business has a 50 day simple moving average of $0.81 and a 200-day simple moving average of $3.73.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.